Resource impact statement

Cancer Drugs Fund technology

NICE has recommended nivolumab with ipilimumab for use within the Cancer Drugs Fund as an option for adults with untreated advanced renal cell carcinoma that is intermediate- or poor-risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria. 

Nivolumab with ipilimumab will be available to the NHS in line with the managed access agreement with NHS England. As part of this, NHS England and Bristol-Myers Squibb have a commercial access agreement that makes nivolumab with ipilimumab available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.

The resource impact of nivolumab with ipilimumab will be covered by the Cancer Drugs Fund budget. The data collection period is expected to end in August 2021, when the analysis of overall survival from CheckMate 214 is available. The aim of the review is to decide whether or not the drug can be recommended for routine use. Further information can be found in NHS England’s Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) - A new deal for patients, taxpayers and industry.

It is estimated that around 1,600 people per year with untreated advanced renal cell carcinoma that is intermediate- or poor-risk are eligible for treatment with nivolumab with ipilimumab.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.


This page was last updated: 15 May 2019